Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study - 25/08/21
Summary |
Background |
Respiratory syncytial virus (RSV) represents a substantial burden of disease in young infants in low-income and middle-income countries (LMICs). Because RSV passive immunisations, including maternal vaccination and monoclonal antibodies, can only grant a temporary period of protection, their effectiveness and efficiency will be determined by the timing of the immunisation relative to the underlying RSV seasonality. We aimed to assess the potential effect of different approaches for passive RSV immunisation of infants in LMICs.
Methods |
We included 52 LMICs in this study on the basis of the availability of RSV seasonality data and developed a mathematical model to compare the effect of different RSV passive immunisation approaches (seasonal approaches vs a year-round approach). For each candidate approach, we calculated the expected annual proportion of RSV incidence among infants younger than 6 months averted (effectiveness) and the ratio of per-dose cases averted between that approach and the year-round approach (relative efficiency).
Findings |
39 (75%) of 52 LMICs included in the study had clear RSV seasonality, defined as having more than 75% of annual RSV cases occurring in 5 or fewer months. In these countries with clear RSV seasonality, the seasonal approach in which monoclonal antibody administration began 3 months before RSV season onset was only a median of 16% (IQR 13–18) less effective in averting RSV-associated acute lower respiratory infection (ALRI) hospital admissions than a year-round approach, but was a median of 70% (50–97) more efficient in reducing RSV-associated hospital admissions per dose. The seasonal approach that delivered maternal vaccination 1 month before the season onset was a median of 27% (25–33) less effective in averting hospital admissions associated with RSV-ALRI than a year-round approach, but was a median of 126% (87–177) more efficient at averting these hospital admissions per dose.
Interpretation |
In LMICs with clear RSV seasonality, seasonal approaches to monoclonal antibody and maternal vaccine administration might optimise disease prevention by dose given compared with year-round administration. More data are needed to clarify if seasonal administration of RSV monoclonal antibodies or maternal immunisation is programmatically suitable and cost effective in LMICs.
Funding |
The Bill & Melinda Gates Foundation, World Health Organization.
Le texte complet de cet article est disponible en PDF.Plan
Vol 21 - N° 9
P. 1303-1312 - septembre 2021 Retour au numéro
Article précédent
- Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance
- The Gambia Pneumococcal Surveillance Group, Grant A Mackenzie, Philip C Hill, David J Jeffries, Malick Ndiaye, Shah M Sahito, Ilias Hossain, Uchendu Uchendu, David Ameh, Oyedeji Adeyemi, Jayani Pathirana, Yekini Olatunji, Baderinwa Abatan, Bilquees S Muhammad, Ebirim Ahameefula, Augustin E Fombah, Banjo Adeshola, Babila G Lobga, Debasish Saha, Roslyn Mackenzie, Aderonke Odutola, Ian D Plumb, Aliu Akano, Bernard E Ebruke, Readon C Ideh, Bankole Kuti, Peter Githua, Emmanuel Olutunde, Ogochukwu Ofordile, Edward Green, Effua Usuf, Henry Badji, Usman NA Ikumapayi, Ahmed Manjang, Rasheed Salaudeen, E David Nsekpong, Sheikh Jarju, Martin Antonio, Sana Sambou, Lamin Ceesay, Yamundow Lowe-Jallow, Sidat Fofana, Momodou Jasseh, Kim Mulholland, Maria Knoll, Orin S Levine, Stephen R Howie, Richard A Adegbola, Brian M Greenwood, Tumani Corrah
- Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial
- Bruno François, Hasan S Jafri, Jean Chastre, Miguel Sánchez-García, Philippe Eggimann, Pierre-François Dequin, Vincent Huberlant, Lucia Viña Soria, Thierry Boulain, Cédric Bretonnière, Jérôme Pugin, Josep Trenado, Ana Catalina Hernandez Padilla, Omar Ali, Kathryn Shoemaker, Pin Ren, Frank E Coenjaerts, Alexey Ruzin, Olivier Barraud, Leen Timbermont, Christine Lammens, Vadryn Pierre, Yuling Wu, Julie Vignaud, Susan Colbert, Terramika Bellamy, Mark T Esser, Filip Dubovsky, Marc J Bonten, Herman Goossens, Pierre-François Laterre, COMBACTE Consortium and the SAATELLITE Study Group, Didier Chochrad, Alain Dive, Frédéric Foret, Marc Simon, Herbert Spapen, Jacques Creteur, Yves Bouckaert, Patrick Biston, Marc Bourgeois, Martin Novacek, Tomas Vymazal, Petr Svoboda, Jan Pachl, Vladimir Sramek, Michal Hanauer, Tomas Hruby, Martin Balik, Tomas Suchy, Alain Lepape, Laurent Argaud, Frédéric Dailler, Arnaud Desachy, Christophe Guitton, Alain Mercat, Ferhat Meziani, Jean-Christophe Navellou, Rene Robert, Bertrand Souweine, Jean-Marc Tadie, Adel Maamar, Djillali Annane, Fabienne Tamion, Antoine Gros, Saad Nseir, Carole Schwebel, Gilles Francony, Jean-Yves Lefrant, Francis Schneider, Matthias Gründling, Johann Motsch, Lorenz Reill, Caroline Rolfes, Tobias Welte, Oliver Cornely, Frank Bloos, Maria Deja, Katrin Schmidt, Frank Wappler, Andreas Meier-Hellmann, Apostolos Komnos, Vasileios Bekos, Vasilios Koulouras, Ioanna Soultati, Georgios Baltopoulos, Georgios Filntisis, Epaminondas Zakynthinos, Spyros Zakynthinos, Ioannis Pnevmatikos, Ildikó Krémer, Zoltán Szentkereszty, Agnes Sarkany, Zsuzsa Marjanek, Pedro Moura, Maria Consuelo Pintado Delgado, Juan Carlos Montejo González, Paula Ramirez, Antonio Torres Marti, Juan Carlos Valia, Jose Lorente, Ana Loza Vazquez, Raúl De Pablo Sanchez, Dolores Escudero, Ricard Ferrer Roca, Jean-Luc Pagani, Marco Maggiorini
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?